Jade Biosciences (JBIO) Free Cash Flow Growth (1y) (2021 - 2026)
Jade Biosciences (JBIO) Free Cash Flow Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,861.65 Bn | 66,861.36 Bn | - | 7.12% |
| 2 | Nanobiotix | 1,910.87 Bn | 1,910.81 Bn | - | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 1,092.51% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 66.37% |
| 6 | Regeneron Pharmaceuticals | 69.90 Bn | 61.14 Bn | 3.31 Bn | 3.98% |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - | - |
| 8 | Argenx Se | 55.83 Bn | 50.65 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.46 Bn | 37.46 Bn | - | - |
| 10 | Jade Biosciences | 1.19 Bn | 878.34 Mn | - | -28.90% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -28.90% |
| Dec 31, 2025 | -46.69% |
| Sep 30, 2025 | -162.88% |
| Jun 30, 2025 | -902.67% |
| Mar 31, 2025 | 21.01% |
| Dec 31, 2024 | -53.99% |
| Sep 30, 2024 | 45.52% |
| Jun 30, 2024 | 116.77% |
| Mar 31, 2024 | -106.66% |
| Dec 31, 2023 | 10.36% |
| Sep 30, 2023 | -64.96% |
| Jun 30, 2023 | -61.27% |
| Mar 31, 2023 | -101.34% |
| Dec 31, 2022 | -26.50% |
| Sep 30, 2022 | -45.44% |
| Jun 30, 2022 | -131.61% |
| Mar 31, 2022 | -49.12% |
| Dec 31, 2021 | -353.54% |
| Sep 30, 2021 | -167.98% |